Skip to content

Evaluation of the effect of Clen Plus capsules on vancomycin-induced nephrotoxicity

Evaluation of the effect of Clen Plus capsules on vancomycin-induced nephrotoxicity

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210405050857N1
Enrollment
30
Registered
2021-04-17
Start date
2021-04-13
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of Cellen Plus capsules on vancomycin-induced nephrotoxicity.

Interventions

Intervention 1: Intervention group: Selen Plus capsules every 12 hours for three days, manufactured by Iran under the license of Germany, whose ingredients are selenium 50ug, vitamin C 125mg, zinc 8mg

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Months to 18 Years

Inclusion criteria

Inclusion criteria: Patients with systemic infection treated with vancomycin Complete the informed consent form

Exclusion criteria

Exclusion criteria: Concurrent renal failure Concomitant use of another nephrotoxic drug Patients with severe dehydration Patients with elevated urea and creatinine at baseline and initial testing

Design outcomes

Primary

MeasureTime frame
Urine microalbumin. Timepoint: At the beginning of the study (before the intervention) and 72 hours after the start of taking Selen Plus capsules. Method of measurement: Urine tests.

Secondary

MeasureTime frame
Urea. Timepoint: At the beginning of the study (before the start of the intervention) and 72 hours after the start of taking Selen Plus capsules. Method of measurement: Blood test.;Creatine. Timepoint: At the beginning of the study (before the start of the intervention) and 72 hours after the start of taking Selen Plus capsules. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYosra Mohammadi Yazdi

Sabzevar University of Medical Sciences

yosramohammadiyazdi@gmail.com+98 51 3841 9584

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026